Blood-derived Product Market Trends and Forecast
The future of the global blood-derived product market looks promising with opportunities in the therapeutic and excipient markets. The global blood-derived product market is expected to grow with a CAGR of 6.5% from 2025 to 2031. The major drivers for this market are the increasing demand for plasma-derived therapies, the rising adoption of blood transfusion technologies, and the growing awareness of blood donation.
• Lucintel forecasts that, within the type category, immunoglobulin is expected to witness the highest growth over the forecast period.
• Within the application category, therapeutic is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Blood-derived Product Market
The blood-derived product market is transforming quickly as a result of increased immunoglobulin demand, enhanced plasma processing, the advent of recombinant alternatives, increasing preference for subcutaneous therapy, and a greater emphasis on sustainable plasma collection.
• Growing Demand for Immunoglobulins: There is a growing incidence of autoimmune diseases, primary and secondary immunodeficiencies, and neurological disorders all over the world, resulting in an increased demand for immunoglobulin treatments. This trend is forcing producers to expand production capacity and come up with more effective purification processes in order to address the increasing clinical demands.
• Technological Developments in Plasma Fractionation: Advances in separation methods such as chromatography and filtration are increasing the yield and efficiency of plasma protein isolation. Automated processes are simplifying manufacturing, minimizing costs and errors. These developments are important for enhancing the availability and affordability of blood-derived products.
• Increasing Emphasis on Recombinant Options: Although plasma-derived products continue to be critical, there is greater research and development in recombinant options, especially for coagulation factors. These options are designed to decrease dependence on human plasma and improve product safety profiles, representing potential long-term solutions for some therapeutic categories.
• Growth of Subcutaneous Immunoglobulin Therapies: SCIG provides patients with increased convenience and flexibility over intravenous immunoglobulin (IVIG) administration in that it can be self-administered at home. The trend is enhancing patient compliance and quality of life, stimulating demand for SCIG products and their development further.
• Focus on Plasma Collection and Donor Safety: A stable and safe supply of plasma is of utmost importance. There is a heightened focus on building plasma collection networks, enforcing rigorous donor screening procedures, and applying cutting-edge technologies to increase the safety and quality of collected plasma. Ethical sourcing and donor welfare are increasingly significant considerations.
These trends are transforming the blood-derived product market by stimulating innovation, expanding access to therapies, and enhancing patient outcomes. The emphasis on technological innovation and alternative treatments is designed to overcome supply issues and improve safety, while increasing demand for individual products such as immunoglobulins requires expansion of manufacture and effective distribution methods.
Recent Development in the Blood-derived Product Market
Recent trends in the blood-derived product industry involve massive investments in plasma collection, advanced manufacturing technologies, improved regulatory approvals, continuous research on new products and uses, and rising focus on sustainability and ethical standards.
• Scaled-Up Investment in Plasma Collection Infrastructure: Everywhere across the globe, firms are scaling up plasma collection networks through the opening of new centers as well as strategy for boosting donor involvement. It is an imperative step to satisfy growing demand for plasma-derived medications. For instance, BIOIIFE, owned by Takeda, introduced new technology that is aimed at making plasma donation more efficient in the US recently.
• Process Manufacturing Advances: Advances in plasma fractionation processes are yielding increased yields and purity of blood-derived products. Advanced chromatography methods and automation are being adopted by companies to enhance efficiency and decrease production costs. These advances provide a more cost-efficient and consistent supply of critical therapies.
• Regulatory Refurbishments and Simplification: Regulatory agencies across different nations are revising their guidelines and simplifying approval procedures for blood-derived products to provide timely access to patients while upholding safety standards. This encompasses efforts to accelerate the review of new treatments and manufacturing procedures.
• Research on New Plasma-Derived Products and Uses: Current research is investigating new therapeutic uses for blood-derived products as well as new formulations with enhanced efficacy and safety profiles. These include such areas as targeted immunotherapies and next-generation coagulation factor concentrates with prolonged half-lives.
• Increasing Priority on Sustainability and Ethical Sourcing: There is a greater emphasis on sustainable practices in plasma collection and production, as well as ethical treatment of donors. Organizations are adopting green processes and increased donor participation to encourage a responsible and sustainable supply chain.
These advances are hugely contributing to the blood-derived product market by making plasma therapies more available, safer, and more effective, while also stimulating development in production and use. The emphasis on regulatory effectiveness and sustainability is likewise influencing the future direction of the market, supporting long-term growth and patient access to these life-saving therapies.
Strategic Growth Opportunities in the Blood-derived Product Market
There are strong strategic growth prospects for blood-derived products in the areas of neurology (autoimmune diseases), immunology (immunodeficiencies, autoimmune disorders), hematology (bleeding disorders), critical care (supportive care), and rare disease treatment.
• Neurology: Neurological disorder growth in Guillain-Barré syndrome and CIDP translates into an especially favorable growth opportunity for immunoglobulin therapies. Growing diagnostic capabilities and increased awareness of the diseases are propelling augmented use of IVIg and SCIG.
• Immunology: The increasing prevalence of primary and secondary immunodeficiency disorders and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis is driving the demand for a variety of blood-derived products, such as immunoglobulins and albumin. Early detection and preventive treatment strategies are broadening this market segment.
• Hematology: Expansion of the patient population suffering from bleeding disorders like hemophilia A and B, and the expanding use of plasma-derived coagulation factors in surgery and trauma treatment, is a big growth opportunity. Extended half-life clotting factor development is further increasing the effectiveness of treatment and convenience to patients.
• Critical Care: Albumin is commonly utilized in the care of critically ill patients with diseases such as sepsis, burns, and liver failure. Increasing numbers of ICU admissions and the growth in critical care medicine are fueling demand for albumin and other plasma-derived products utilized in supportive therapy.
• Rare Diseases: Several rare genetic disorders need to be treated with particular blood-derived products, including alpha-1 antitrypsin deficiency and hereditary angioedema. Heightened awareness, enhanced diagnostic capabilities, and the emergence of new rare disease therapies are giving rise to niche but meaningful growth opportunities within the market.
These growth prospects are influencing the blood-derived product market by promoting focused research and development initiatives, motivating companies to diversify their product offerings, and promoting partnerships with healthcare providers and patient advocacy organizations. Meeting the unique needs of these major application areas is essential to the ongoing growth and development of the market.
Blood-derived Product Market Driver and Challenges
The market for blood-derived products is shaped by a sophisticated interaction of technological, economic, and regulatory influences that serve both as drivers of growth and as sources of difficulty.
The factors responsible for driving the blood-derived product market include:
1. Rising Incidence of Immune and Chronic Disorders: The growing number of autoimmune disorders, immunodeficiencies, bleeding disorders, and other chronic illnesses around the world is a key driver for demand for blood-derived therapies such as immunoglobulins and coagulation factors.
2. Aging Global Population: With the aging of the worldÄX%$%Xs population, age-related diseases and conditions in need of blood-derived products, including some autoimmune diseases and the requirement for albumin in supportive care, are on the rise, thereby fueling market growth.
3. Advances in Therapeutics and Medical Technology: Ongoing innovation with diagnostics and treatment protocols broadens the uses of blood-derived products. For example, advancements in subcutaneous administration routes and products of prolonged half-life increase patient convenience and treatment effectiveness.
4. Rising Awareness and Enhanced Diagnosis: Enhanced awareness among medical professionals and the public, along with improved diagnostic technology, results in earlier and more precise diagnosis of conditions that can be treated with blood-derived products, thus increasing the patient base.
5. Favorable Regulatory Environment: Regulatory authorities in most parts of the world are striving to make approval processes easier for critical blood-derived therapies without compromising on strict safety standards, enabling market access and encouraging innovation.
Challenges in the blood-derived product market are:
1. Plasma Supply Restrictions: The manufacture of blood-derived products is based on human plasma donations, and an adequate and safe supply of plasma is a major challenge. Donor availability, risk for infectious diseases, and the intricacy of the collection process may affect supply.
2. High Production Costs: Fractionation and purification of plasma into therapeutic products are sophisticated and costly processes. High production costs may affect the affordability and availability of these life-saving therapies, especially in poorer regions.
3. Recombinant Alternative Competition: Although not for all blood-derived products, the creation and growing use of recombinant alternatives for some factors, e.g., coagulation factors, represent a competitive threat to the plasma-derived segment.
Overall, the blood-derived product industry is spurred by growing medical demands, innovations in technology, and regulatory support. Yet, it also experiences plasma supply shortages, stringent production costs, and competition from recombinant drugs. Overall, the result is an expanding industry that necessitates constant improvement in plasma collection and processing, strategic partnerships, and effective regulatory systems to provide an ongoing supply of these life-critical therapies.
List of Blood-derived Product Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies blood-derived product companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the blood-derived product companies profiled in this report include-
• Grifols
• CSL
• Takeda
• Octapharma
• CBPO
• Hualan Bio
• Kedrion
• Shanghai RAAS
• LFB Group
• Weiguang
Blood-derived Product Market by Segment
The study includes a forecast for the global blood-derived product market by type, application, and region.
Blood-derived Product Market by Type [Value from 2019 to 2031]:
• Albumin
• Immunoglobulins
• Coagulation Factors
• Others
Blood-derived Product Market by Application [Value from 2019 to 2031]:
• Therapeutics
• Excipient
• Others
Blood-derived Product Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Blood-derived Product Market
Current trends in the blood-derived product market are indicative of a worldwide trend towards greater demand, advances in fractionation technology, and changing regulatory environments. The products, such as immunoglobulins, albumin, and coagulation factors, are essential for the management of many conditions, ranging from immune deficiencies to bleeding disorders. Aging populations, growing incidence of chronic diseases, and developments in plasma collection and processing technologies influence the market. Sustainability and ethical sourcing of plasma are also becoming increasingly important.
• United States: The US market is witnessing tremendous growth fueled by growing needs for immunoglobulins and advances in plasma collection technologies. FDAÄX%$%Xs simplified approval processes are driving faster market penetration. Organizations are working on increasing plasma collection centers and pursuing recombinant substitutes to meet supply woes. Convenience is driving the popularity of subcutaneous immunoglobulin therapies. The market is commanded by players such as CSL Behring, Grifols, and Takeda, which are continuously strengthening their presence.
• China: The blood-derived product market in China is growing aggressively, driven by a rising aging population and growing demand for immunoglobulins. The supportive government policies as well as advances in plasma fractionation are the driving forces behind the market. There is investment from companies in R&D to enhance product efficacy and safety. The market is witnessing more domestic manufacturing and strategic partnerships. Immunoglobulin is a dominant product category, and improved centrifugation and chromatography are improving the efficiency of plasma processing.
• Germany: The German market is dominated by robust regulatory controls and innovation-based growth. High incidence of chronic diseases and regulatory support for plasma therapies are spurring demand. R&D investments and personalized medicines are gaining greater attention. German Medicines Agency is simplifying approval processes. Ethical and sustainable plasma collection and sustainability are significant trends. Immunoglobulin, albumin, and coagulation factors are the critical product types covering a wide spectrum of clinical indications.
• India: Indian blood-derived product industry is growing strongly driven by the rising geriatric population and growing application of immunoglobulins. Domestic manufacturing investments and enhanced plasma-derived therapy awareness are major drivers. Efforts by the government to encourage blood donation are fueling market growth. Hematology and immunology are principal application domains. Players such as Plasma Gen Bio Sciences and Reliance Life Sciences are the major players, with their focus on increasing manufacturing capacity and launching new products such as human fibrinogen concentrate.
• Japan: JapanÄX%$%Xs plasma market is poised to boom due to the countryÄX%$%Xs aging population and advancements in plasma processing technology. Growing use of plasma-derived treatments in medicine and tougher regulatory environments are defining the market. Immunoglobulins and coagulation factors are in greater demand. The domestic manufacture of these products is becoming more vital to curtail import dependence. Companies are making significant investments in R&D and new manufacturing facilities to keep up with increasing demand for these essential treatments.
Features of the Global Blood-derived Product Market
Market Size Estimates: Blood-derived product market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Blood-derived product market size by type, application, and region in terms of value ($B).
Regional Analysis: Blood-derived product market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the blood-derived product market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the blood-derived product market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for blood-derived product market?
Answer: The global blood-derived product market is expected to grow with a CAGR of 6.5% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the blood-derived product market?
Answer: The major drivers for this market are the increasing demand for plasma-derived therapies, the rising adoption of blood transfusion technologies, and the growing awareness of blood donation.
Q3. What are the major segments for blood-derived product market?
Answer: The future of the blood-derived product market looks promising with opportunities in the therapeutic and excipient markets.
Q4. Who are the key blood-derived product market companies?
Answer: Some of the key blood-derived product companies are as follows:
• Grifols
• CSL
• Takeda
• Octapharma
• CBPO
• Hualan Bio
• Kedrion
• Shanghai RAAS
• LFB Group
• Weiguang
Q5. Which blood-derived product market segment will be the largest in future?
Answer: Lucintel forecasts that, within the type category, immunoglobulin is expected to witness the highest growth over the forecast period.
Q6. In blood-derived product market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the blood-derived product market by type (albumin, immunoglobulins, coagulation factors, and others), application (therapeutics, excipient, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Blood-derived Product Market, Blood-derived Product Market Size, Blood-derived Product Market Growth, Blood-derived Product Market Analysis, Blood-derived Product Market Report, Blood-derived Product Market Share, Blood-derived Product Market Trends, Blood-derived Product Market Forecast, Blood-derived Product Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.